Navigation Links
Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
Date:5/6/2009

Current and Emerging Targeted Therapies Such As AstraZeneca's Iressa and Roche's Avastin Will Drive the Market From 2008 to 2013, According to a New Report from Decision Resources

WALTHAM, Mass., May 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in China will more than double by 2013, growing from $307 million in 2008 to $648 million in 2013. This growth will be fueled by a large increase in non-small-cell lung cancer diagnosed incident cases, improvement in access to medical care and significantly increased prescribing of targeted therapies.

"Urbanization and an aging population will result in a 47 percent increase in the number of diagnosed incident cases of non-small-cell lung cancer in China during 2008 to 2018. The most significant increase will occur in urban China, where we expect the number of diagnosed incident cases to increase 72 percent, in contrast to just eight percent in rural regions by the end of the 2018," stated Jing Wu, M.S., MBA.

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in China also finds that increased penetration of current targeted therapies such as AstraZeneca's Iressa (gefitinib), Roche's Tarceva (erlotinib) and Jiangsu Simcere's Endostar (endostatin) and the launch of new targeted therapies -- Roche's Avastin (bevacizumab) and Merck KGaA's Erbitux (cetuximab) -- are the main driving forces in the Chinese non-small-cell lung cancer market from 2008 to 2013.

"In 2008, sales of non-small-cell lung cancer drugs in China totaled $307 million -- a 13 percent increase from our 2006 report," added Ms. Wu. "In 2008, the increased prescription of Iressa, Tarceva and Endostar was the major factor contributing to this market growth."

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. High alcohol consumption increases stroke risk among Chinese men
2. Heavy Drinking Boosts Stroke Risk for Chinese Men
3. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
4. Chinese takeaway in the Wadden Sea
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. China Shenghuo Pharmaceutical Holdings, Inc. Opens Showcase 12Ways(R) Chinese Herbal Beauty Salon in October
7. CHRI Receives Approval for Suining Chuan DAR Authentication Trademark From Chinese Government
8. All-State Properties, L.P. Announces Termination of Reverse Merger With Chinese Pharmaceutical Company
9. Rh-Apo2L Named as One of Chinas High-Tech Transforming Products by Chinese Government
10. What are the essential characteristics of serum PG in Chinese?
11. Linkwell Chairman & CEO Addresses the Association of Chinese Nosocomial Infections Professional Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards for ... spectrum of disordered eating, announced today that the 2017 Symposium set a new attendance ... several countries converged on the Green Valley Resort in Las Vegas. , “We ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
(Date:3/24/2017)... ... 24, 2017 , ... Empower Brokerage, located in Southlake, Texas, ... programs. , In February, 2017, Empower Brokerage introduced their new “Performance Partners” program ... to teach how to maximize their sales efforts, as well as how to ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... services to their communities, 16 more public health departments have been awarded national ... bring another 4.5 million people into the expanding network of communities across the ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... ShangPharma, a leading life science ... development and discovery services, technology, and investment ... today the intent for a strategic corporate ... the Contract Research Organizations (CRO) and Contract ... entities include ChemPartner Shanghai, ChemPartner Fengxian, ChemPartner ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Diagnostics, 2017 - 2035" report to their offering. ... The Deep Learning: Drug Discovery ... outlook of the growing market of deep learning solutions within the ... algorithms have emerged as a novel solution to generate relevant insights ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: